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Formalin-fixed, paraffin-embedded (FFPE) tissue archives are the largest and longest time-spanning collections of patient material in
pathology archives. Methods to disclose information with molecular techniques, such as array comparative genomic hybridisation
(aCGH) have rapidly developed but are still not optimal. Array comparative genomic hybridisation is one efficient method for finding
tumour suppressors and oncogenes in solid tumours, and also for classification of tumours. The fastest way of analysing large numbers
of tumours is through the use of archival tissue samples with first, the huge advantage of larger median follow-up time of patients
studied and second, the advantage of being able to locate and analyse multiple tumours, even across generations, from related
individuals (families). Unfortunately, DNA from archival tissues is not always suitable for molecular analysis due to insufficient quality.
Until now, this quality remained undefined. We report the optimisation of a genomic-DNA isolation procedure from FFPE pathology
archives in combination with a subsequent multiplex PCR-based quality-control that simply identified all samples refractory to further
DNA-based analyses.
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Cancer cytogenetics has benefited greatly from the introduction
of comparative genomic hybridisation (CGH) for mapping
chromosomal gains and losses at a genome-wide scale (Kallioniemi
et al, 1993; Gray et al, 1994). Subsequent development of the
technique into array-CGH (also named matrix-CGH) has allowed
increased automation, improved reproducibility and precision due
to more accurate mapping of aberrations. This technology has
been applied successfully to characterise congenital abnormalities
at unprecedented precision (Veltman et al, 2002) and to
characterise and classify tumours (Wessels et al, 2002; Nessling
et al, 2005).
In most pathology laboratories, large archives of formalin-fixed,
paraffin embedded (FFPE) material are often the only source of
material for cancer research. It is our experience (Wessels et al,
2002; Van Beers et al, 2005) that a proportion of archival
specimens appears unsuited for aCGH analysis, which is trouble-
some because array comparative genomic hybridisation (aCGH)
experiments are tedious and expensive. In the past, we have
noticed that this was not solved by repeating aCGH experiments,
even when DNA was isolated from new sections from the same
tissue blocks (Van Beers et al, 2005). Nevertheless, it is possible to
obtain high-quality data using archival DNA samples in array CGH
experiments (Figure 1) (Gray et al, 1994; Ried et al, 1995;
Albertson and Pinkel, 2003; Heidenblad et al, 2004; Loo et al, 2004;
Devries et al, 2005), even from 20-year-old tissue blocks, provided
that robust procedures, high-quality reagents and ‘good’ sample
DNA quality are being used. A ‘good sample quality’ definition and
an assay to determine this FFPE DNA sample quality would
therefore be of great value.
Molecular biological assays, including aCGH on FFPE
archival specimens, would be more efficient when good and bad
quality samples were identified prior to aCGH assays, by a quick,
cheap, simple and reliable assay. Variability, mostly in sample
fixation (time), and also duration of storage affect DNA quality.
Improvements in many pathology laboratories in sample handling,
including shortening of the fixation duration to 24–48h and using
buffered formalin may have contributed to the increased quality of
tissue-extracted DNA (Legrand et al, 2002). In an attempt to
predict the success of aCGH hybridisation, many laboratories have
assessed DNA quality by DNA gel electrophoresis. Although such
analyses provide information on the size, amount and distribution
of the fragment sizes of the (partially) degraded DNA, this did not
correlate well with aCGH success in our hands. Our hypothesis is
that apart from the fragment length, DNA crosslinks caused by
fixation are of major importance for hybridisation results. We
therefore focused on improvement of the DNA isolation method to
reduce DNA crosslinks, and on an assay to determine the
abundance of DNA crosslinks as a measure of DNA quality. This
prompted us to evaluate retrospectively our good and bad aCGH
experiments and devise a method that indicates DNA quality
and aCGH success. This resulted in a modified DNA isolation
method and a quality test using a multiplex-PCR assay for sample
DNA quality control together with measurement of specific
labeling of Cyanin cis-platinum-labelled nucleotides in the test
DNA.
Received 25 August 2005; accepted 1 October 2005; published online 6
December 2005
*Correspondence: Dr EH van Beers, room H604, Plesmanlaan 121, 1066
Cx Amsterdam, The Netherlands; E-mail: e.v.beers@nki.nl
British Journal of Cancer (2006) 94, 333–337
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sMATERIALS AND METHODS
DNA isolation
Genomic DNA was isolated from 10 10mm-thick paraffin-
embedded tissue sections. Sections were deparaffinated twice for
5min in xylene, rehydrated in 100, 96 and 70% ethanol for 30s
each, stained with haematoxylin for 30s, rinsed with water and
incubated overnight in 1 M NaSCN at 371C to remove crosslinks.
Slides were rinsed twice 10min in 1  PBS at room temperature,
and completely air-dried. Tumour tissue was scraped from the
glass with a scalpel to obtain at least 70% tumour cells in 200ml
Qiagen ATL buffer (QIAamp
s DNA extraction kit cat. 51306),
transferred to eppendorf tubes and incubated with 27ml protei-
nase-K (20mg/ml stock) at 450rpm (Eppendorf
s Thermomixer R)
at 551C. Three more aliquots of 27ml proteinase-K were added at 4,
20 and 28h. After a total protK incubation of B44h, DNA
isolation proceeded as in the manufacturer’s protocol (Qiagen, Cat.
51306). Samples of isolated genomic DNA were analysed by 0.8%
agarose gel electrophoresis to visualise DNA concentration and
size distribution. In case of tumour tissue, we scraped regions
containing at least 70% tumour as indicated by an experienced
breast cancer pathologist. aCGH reference DNA was isolated from
peripheral blood lymphocytes from six apparently healthy female
individuals. It was pooled and sonicated until its median fragment
length was similar to that of the test samples.
Multiplex PCR
We analysed 100ng as measured by optical density at 260/280nm
of each archival genomic DNA sample by a multiplex PCR. The
PCR reaction was performed with four primer sets that produce
100, 200, 300 and 400bp fragments from nonoverlapping target
sites in the GAPDH gene (chr12) in 30ml with final concentrations:
0.133mM of each of the following eight 50–30primers: 100F
gttccaatatgattccaccc; 100R ctcctggaagatggtgatgg; 200F aggtggagc
gaggctagc; 200R ttttgcggtggaaatgtcct; 300F aggtgagacattcttgctgg;
300R tccactaaccagtcagcgtc; 400F acagtccatgccatcactgc and 400R
gcttgacaaagtggtcgttg in a reaction with 10mM Tris-HCl pH 8.8,
1.5mM MgCl2,7 5 m M KCl, 0.2mM dNTPs, 1U Taq DNA-
polymerase (Invitrogen cat. 18038-26). PCR was performed in
thin-wall tubes in an MJ Research PCR apparatus for 4min 941C,
35 cycles each of 1min 941C, 1min 561C and 3min 721C, followed
by 7min 721C ending at 151C. After addition of 6ml( 5 ) loading
dye, 10ml of each sample was analysed on a 1.5% TBE agarose
ethidium bromide-stained gel. Samples were classified based on
the largest of four possible PCR products detected, namely 100,
200, 300 and 400bp. The GAPDH genomic target for amplification
is more or less arbitrary but the lengths of the products were
purposely chosen based on earlier experience with FFPE DNA
amplification (MJL, unpublished results).
Genomic DNA labelling
All labelling reactions were performed with the Cy3 and Cy5
conjugates from the Universal Linkage System (ULS, Kreatech
Biotechnology, Amsterdam the Netherlands) (Raap et al, 2004)
Labelling efficiency for ULS-Cy3 and ULS-Cy5 were calculated
from A260 (DNA), A280 (protein), A550 (Cy3) and A649 (Cy5) after
removal of unbound ULS, on a NanoDrop
sND-1000 spectro-
photometer (NanoDrop Technologies, Wilmington, DE, USA). The
degree of labeling (DOL) was calculated from the specific molar
extinction ratios for Cy3, Cy5 and DNA and must be between 1 and
4% (between 1 and 4 ULS molecules per 100bp) for optimal
hybridisation signals.
Array CGH
The human 3600 BAC/PAC genomic clone set, covering the full
genome at 1Mb spacing used for the production of our arrays, was
obtained from the Welcome Trust Sanger Institute (http://
www.sanger.ac.uk/). Information on this clone set can be obtained
at the BAC/PAC Resources Center Web Site (http://bacpac.chori.
org). Degenerate oligonucleotide PCR-products from all BAC
clones were prepared for spotting on CodeLinkt Activated Slides
(Amersham Biosciences, Prod. No. 300011 00) according to
detailed protocols (Pinkel et al, 1998) with some modifications
(Alers et al, 1999). All clones (three replicates for each probe) were
spotted in randomised fashion across 48 subarrays, each contain-
ing 270 spots and hybridised for 48–72h at 371C on an orbital
shaker (300rpm) in a humidified chamber with 2mg tumour-DNA
labelled with ULS-Cy5 and 2mg sonicated lymphocyte control DNA
labelled with ULS-Cy3. After washing, arrays were scanned on a
Microarray Scanner (G2505B Agilent Technologies), and spots
quantified with ImaGene
s software (version 6.0.1 BioDiscovery,
Marina Del Rey, CA, USA). Computation of the profiles included
local background subtraction, Cy5/Cy3 ratio,
2log-transformation
and subarray normalisation to its median. The
2log ratios for all
nonflagged spots are then plotted (Figure 2D) along with the
standard deviation for each triplicate as smaller dots (red) closer to
the X-axis using the secondary y-scale to the right. Bad
morphology or uniformity spots were flagged in ImaGene
s. When
flagged spots accounted for 45% of all spots, hybridisations were
excluded. The BAC clones are ordered by position as assigned by
NCBI-Build35 (http://genome.ucsc.edu/cgi-bin/hgGateway) in the
genome beginning at the telomere of 1p and ending at the telomere
of Yq.
RESULTS AND DISCUSSION
In a systematic approach, we have identified and optimised the
selection steps for FFPE archival material to be used in down-
stream applications, particularly for aCGH.
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Figure 1 A total of 12 unselected DNA preparations from FFPE breast
tumours with corresponding multiplex PCR quality controls. (A) DNA was
isolated from archival blocks stored between 6 (lane b) and 29 (lane l)
years. Lane M indicates the molecular size standard (bp). Sample a through l
were fixed and stored 11, 6, 22, 20, 18, 11, 8, 7, 19, 17, 16 and 29 years
ago, respectively. Lanes in bold a, b, d, f, h, j and k indicate samples with
successful aCGH. The oldest samples in this panel successful in aCGH are
in lanes d, k and j (20, 17 and 16 years). (B) Agarose gel showing multiplex
PCR product sizes in bp (see Materials and Methods) for the corresponding
samples above.
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In the past, we have used size and size distribution of genomic
DNA as a surrogate quality end point. The resulting aCGH profiles
were sometimes inconsistent with the estimated sample quality.
Figure 1A shows a typical series of 12 isolated genomic DNA
samples from FFPE tissue sections. Each lane contains 5ml (10%)
of each isolate. The oldest sample was embedded and stored 26
years before DNA extraction (lane L). The amount of DNA is
variable due to the variability in number of nuclei, and dependent
on size of the tissue scraped. Furthermore, Figure 1A shows that
genomic DNA from archival tissue is severely fragmented with an
estimated median DNA fragment size often below 1kb and varies
substantially between samples (cf. lanes B vs J). In addition, we
observed variability in the size distribution (i.e. long vs short
smear) between samples (cf. lanes B vs J).
Multiplex PCR quality assay
An unknown fraction of these samples are refractory to molecular
assays including aCGH. The challenge was to identify these
samples before performing aCGH. We hypothesised that FFPE
samples even after de-crosslinking may still contain DNA cross-
links that prevent specific hybridisation and therefore render the
sample useless for aCGH. We assumed that with increasing
occurrence of DNA crosslinks, the 400, 300, 200 and 100bp PCR
products would become less abundant or even disappear in that
order. We thus used the relative amounts of the four possible PCR
products as a reporter of DNA quality, and therefore suitability in
aCGH. Our quality assay requires 100ng genomic DNA of each
sample in a single multiplex PCR reaction. Representative archival
DNA preparations are shown in Figure 1. Two samples (e and l)
failed to produce the 100bp PCR fragment (Figure 1B) and were
not successful in subsequent aCGH. Three samples (c, g, i) only
produced the 100bp fragment and each failed in aCGH. All seven
samples with a PCR displaying fragments of 200bp or more were
successful in aCGH. Then, we tested DNA samples retrospectively
for cases (N¼26) (Table 1) with known aCGH outcome. We found
a good correlation between the ability to obtain PCR products and
the quality of the aCGH experiment. There were 24 samples with
PCR product and two without (Table 1). The two samples without
PCR product as well as two out of three samples with the 100bp
PCR fragment only were not successful in aCGH (cf. Figure 2D
lower panel). All samples with a 200bp or greater size PCR
fragments resulted in successful aCGH profiles (cf. Figure 2D
upper panel). Then, in a prognostic approach, we used the
multiplex assay outcome to decide when to perform aCGH, that is,
aCGH was only performed if a sample had at least the 100bp PCR
fragment (83 of 93 samples). Only six of 37 (16%) samples that had
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Figure 2 aCGH success is determined by the ability to PCR-amplify fragments of 4 100bp from the sample (FFPE) DNA template. (A) 0.8% agarose gel
electrophoresis shows amount, size and smear-lengths of sample DNA isolated from FFPE tumour tissues. (B) Multiplex-PCR reveals whether a 100, 200,
300 or 400bp fragment are amplified from 100ng total genomic DNA. (C) Representative partial images of array CGH hybridisations. Array CGH was
performed on 3500, DOP-amplified BAC-DNA microarrays (see Materials and Methods) printed on Codelink
s slides. (D) Gain and loss profiles were
plotted where the ordinate represents the log 2 ratio for the mean of triplicates for each BAC, and abscissa the mapping on the genome (from chromosome
1 to Y, left to right). In red, the standard deviation of the triplicate measurements is plotted to a secondary Y-axis on the right.
Table 1 Correlation between PCR result and subsequent successful
array comparative genomic hybridisation (aCGH)
(A) Retrospective correlation of 26 breast tumour formalin-fixed,
paraffin-embedded (FFPE) DNA samples aCGH success with
performance of their multiplex PCR
DNA quality
vs aCGH
Success
(%)
Good
aCGH
Failed
aCGH N
400bp 100 11 11
300bp 100 8 8
200bp 100 2 2
100bp 33 1 2 3
No product 0 — 2 2
Totals 22 4 26
(B) Prospective correlation of 93 breast tumour FFPE DNA samples
aCGH success with performance of their prior multiplex PCR
Largest
product in
multiplex
PCR
Success
(%)
Good
aCGH
Failed
aCGH
Not done N
400bp (100%) 100 2 0 2
300bp 100 5 0 5
200bp 97 38 1 39
100bp 16 6 31 37
No product ND 0 0 10 10
Totals 51 32 10 93
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For the samples with 200bp as the largest product, 38 of 39 (97%)
resulted in good aCGH profiles. All seven samples with a 300 or
400bp products were successful in subsequent aCGH. These
results indicate that samples without a 100bp fragment should not
be used in aCGH and that DNA samples with amplification of the
200bp fragment or larger seem to be of sufficient quality for aCGH
analysis.
aCGH profiles for FFPE breast tumour samples
Figure 2 illustrates our findings on aspects of DNA quality vs
aCGH success. All four upper panels represent a good quality
archival DNA sample, whereas the four lower panels represent a
poor quality archival DNA sample. Both panels A show the amount
and fragment size distribution for these samples after isolation
without further restriction digestion. Even though the DNA
fragments from the lower sample are somewhat smaller, both
DNA samples theoretically consist of appropriately sized frag-
ments for aCGH. Both panels B show the result of multiplex quality
control PCR using 100ng of input DNA. It is here, and only here,
that we detect the crucial difference between good and bad
samples, defined as a minimum of 200bp amplifiable target
sequence. Both panels C show the resulting hybridisation and are
highly similar in quality (area shown is not the same for both
arrays). Finally, panels D show gains (positive log ratios) and
losses (negative log ratios) of (parts of) chromosomal material in
the breast tumours. The upper panel shows a successful aCGH
experiment whereas the lower panel represents a ‘noisy’ and
therefore useless aCGH. Each black dot of the profile represents
the mean of three replicates on the same array (triplicate) and the
standard deviation of the replicate is plotted below to a secondary
Y-scale on the right. Most standard deviations are well below 0.2
and many below 0.1, which indicate very reproducible hybridisa-
tions for the good but notably also for the bad DNA sample. The
decisive difference between good and bad samples that can be
easily scored is the presence of the 200bp multiplex PCR fragment.
DNA quality from three pathology archives across three
decades
With our DNA isolation protocol, we were able to obtain high-
quality DNA from the majority of samples from different
pathology archival paraffin blocks as old as 25 years. An
independent estimation of DNA quality in FFPE samples that
almost entirely consisted of samples from our own institute was
calculated using a different PCR, in this case generating a 157bp
fragment on 1345 samples, 1264 (94%) of which were positive in
this PCR. We found no evidence for different success rates of the
157bp PRC using samples fixed during the last 25 years studied,
whereas DNA from samples fixed before 1970 was often
problematic defined by the failure to produce the 157bp PCR
fragment (results not shown). There were 202 of 246 (82%) positive
PCR reactions in samples fixed between 1970 and 1980, 666 of 682
(97%) samples fixed between 1980 and 1990, and 397 of 418 (95%)
fixed after 1990 (M Schmidt, NKI/AvL personal communication).
There appeared to be a surprisingly large difference between the
archives that we sampled. We then compared the multiplex PCR
quality assessment across three FFPE breast cancer sample series
mentioned in this study, that is, 26 retrospective samples, 93
prospective samples and, the independent study of 1345 breast
cancer samples for which PCR success rates were 85, 55 and 94%,
respectively. Although, the latter percentage (94%) in this
comparison is undoubtedly an overestimation due to the fact that
it is only analysed for production of a 157bp fragment compared
to 200bp fragment in the other two series, it seems that no a priori
success rate can be assumed when different archives are being
sampled.
DpnII digestion or not?
Array CGH requires that high molecular weight genomic DNA is
fragmented to an appropriate fragment size (e.g. by sonication or
restriction digestion). Fragmentation can be omitted for aCGH
when DNA is isolated from FFPE archival material since it is
already fragmented. We compared array CGH using archival DNA
with and without prior DpnII restriction and found similar results
(data not shown). As expected, DNA gel electrophoresis of archival
DNA samples clearly showed the typically fragmented DNA for
FFPE samples (Figure 1) explaining why restriction digestion is
unnecessary on such samples.
CONCLUSION
Since concentration and size distribution (as assessed by ethidium
bromide agarose gel electrophoresis) of genomic DNA isolated
from FFPE tissue are inadequate predictors per se for aCGH
success, we have developed a method for DNA isolation from FFPE
tissue with a subsequent simple and reliable multiplex PCR
protocol that predicted successful aCGH with high accuracy. Of
our archival samples, 11% (12 out of 107) proved unsuitable for
any of the four PCR products and were refractory to aCGH
analysis. Furthermore, when genomic DNA was reisolated from
adjacent serial sections of those paraffin tissue blocks that failed
the multiplex PCR test and aCGH, both multiplex PCR and aCGH
results remained unchanged indicating that DNA suitability for
aCGH seems intrinsic to the embedded tissue and is probably
related to tissue treatment and duration of storage. Finally, the
157bp product PCR was used to assess the quality of a much larger
set of 1345 DNA samples isolated from three independent
pathology archives from samples fixed between 1970 and present.
This series was positive for the 157bp PCR in 94% of the cases,
suggesting that aCGH should be widely applicable to archival
samples when isolated and selected as indicated above.
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